28689178|t|Sacubitril/valsartan: beyond natriuretic peptides.
28689178|a|Natriuretic peptides, especially B-type natriuretic peptide (BNP), have primarily been regarded as biomarkers in heart failure (HF). However, they are also possible therapeutic agents due to their potentially beneficial physiological effects. The angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan, simultaneously augments the natriuretic peptide system (NPS) by inhibiting the enzyme neprilysin (NEP) and inhibits the renin-angiotensin-aldosterone system (RAAS) by blocking the angiotensin II receptor. It has been shown to improve mortality and hospitalisation outcomes in patients with HF due to left ventricular systolic dysfunction. The key advantage of sacubitril/valsartan has been perceived to be its ability to augment BNP, while its other effects have largely been overlooked. This review highlights the important effects of sacubitril/valsartan, beyond just the augmentation of BNP. First we discuss how NPS physiology differs between healthy individuals and those with HF by looking at mechanisms like the overwhelming effects of RAAS on the NPS, natriuretic peptide receptor desensitisation and absolute natriuretic deficiency. Second, this review explores other hormones that are augmented by sacubitril/valsartan such as bradykinin, substance P and adrenomedullin that may contribute to the efficacy of sacubitril/valsartan in HF. We also discuss concerns that sacubitril/valsartan may interfere with amyloid-beta homeostasis with potential implications on Alzheimer's disease and macular degeneration. Finally, we explore the concept of 'autoinhibition' which is a recently described observation that humans have innate NEP inhibitory capability when natriuretic peptide levels rise above a threshold. There is speculation that autoinhibition may provide a surge of natriuretic and other vasoactive peptides to rapidly reverse decompensation. We contend that by pre-emptively inhibiting NEP, sacubitril/valsartan is inducing this surge earlier during decompensation, resulting in the better outcomes observed.
28689178	0	10	Sacubitril	Chemical	MESH:C000717211
28689178	11	20	valsartan	Chemical	MESH:D000068756
28689178	29	49	natriuretic peptides	Chemical	MESH:D045265
28689178	51	71	Natriuretic peptides	Chemical	MESH:D045265
28689178	84	110	B-type natriuretic peptide	Gene	4879
28689178	112	115	BNP	Gene	4879
28689178	164	177	heart failure	Disease	MESH:D006333
28689178	179	181	HF	Disease	MESH:D006333
28689178	319	329	neprilysin	Gene	4311
28689178	341	351	sacubitril	Chemical	MESH:C000717211
28689178	352	361	valsartan	Chemical	MESH:D000068756
28689178	449	459	neprilysin	Gene	4311
28689178	461	464	NEP	Gene	4311
28689178	483	488	renin	Gene	5972
28689178	639	647	patients	Species	9606
28689178	653	655	HF	Disease	MESH:D006333
28689178	663	700	left ventricular systolic dysfunction	Disease	MESH:D018487
28689178	723	733	sacubitril	Chemical	MESH:C000717211
28689178	734	743	valsartan	Chemical	MESH:D000068756
28689178	792	795	BNP	Gene	4879
28689178	899	909	sacubitril	Chemical	MESH:C000717211
28689178	910	919	valsartan	Chemical	MESH:D000068756
28689178	953	956	BNP	Gene	4879
28689178	1045	1047	HF	Disease	MESH:D006333
28689178	1181	1203	natriuretic deficiency	Disease	MESH:D007153
28689178	1271	1281	sacubitril	Chemical	MESH:C000717211
28689178	1282	1291	valsartan	Chemical	MESH:D000068756
28689178	1300	1310	bradykinin	Gene	3827
28689178	1312	1323	substance P	Gene	6863
28689178	1328	1342	adrenomedullin	Gene	133
28689178	1382	1392	sacubitril	Chemical	MESH:C000717211
28689178	1393	1402	valsartan	Chemical	MESH:D000068756
28689178	1406	1408	HF	Disease	MESH:D006333
28689178	1440	1450	sacubitril	Chemical	MESH:C000717211
28689178	1451	1460	valsartan	Chemical	MESH:D000068756
28689178	1480	1492	amyloid-beta	Gene	351
28689178	1536	1555	Alzheimer's disease	Disease	MESH:D000544
28689178	1681	1687	humans	Species	9606
28689178	1700	1703	NEP	Gene	4311
28689178	1879	1887	peptides	Chemical	MESH:D010455
28689178	1967	1970	NEP	Gene	4311
28689178	1972	1982	sacubitril	Chemical	MESH:C000717211
28689178	1983	1992	valsartan	Chemical	MESH:D000068756
28689178	Negative_Correlation	MESH:C000717211	MESH:D018487
28689178	Association	MESH:D006333	3827
28689178	Negative_Correlation	MESH:D000068756	4311
28689178	Negative_Correlation	MESH:C000717211	4311
28689178	Positive_Correlation	MESH:C000717211	133
28689178	Negative_Correlation	MESH:C000717211	MESH:D006333
28689178	Association	MESH:D006333	6863
28689178	Positive_Correlation	MESH:D000068756	133
28689178	Association	MESH:D000068756	MESH:D000544
28689178	Association	MESH:D006333	133
28689178	Negative_Correlation	MESH:D000068756	MESH:D006333
28689178	Negative_Correlation	MESH:C000717211	5972
28689178	Negative_Correlation	MESH:D000068756	5972
28689178	Positive_Correlation	MESH:D000068756	4879
28689178	Positive_Correlation	MESH:D000068756	3827
28689178	Association	MESH:C000717211	351
28689178	Positive_Correlation	MESH:C000717211	6863
28689178	Positive_Correlation	MESH:D000068756	6863
28689178	Negative_Correlation	MESH:D000068756	MESH:D018487
28689178	Association	MESH:D045265	MESH:D006333
28689178	Positive_Correlation	MESH:C000717211	3827
28689178	Association	MESH:C000717211	MESH:D000544
28689178	Association	MESH:D006333	4879
28689178	Association	MESH:D000544	351
28689178	Positive_Correlation	MESH:C000717211	4879

